About
Immunogene Therapy
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapySouthwestern U.S.
Team (25)
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
250
By Phase
PHASE1/PHASE2: 4
By Status
RECRUITING: 2TERMINATED: 2
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT05703971Lead Sponsor
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
PHASE1/PHASE2Recruiting
62 participants
Started: May 9, 2024 · Completed: Aug 31, 2027
NCT05062980Lead Sponsor
Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer
PHASE1/PHASE2Terminated
5 participants
Started: Mar 30, 2022 · Completed: Feb 3, 2025
NCT04486833Lead Sponsor
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
PHASE1/PHASE2Recruiting
158 participants
Started: Sep 3, 2021 · Completed: Mar 31, 2029
NCT01455389Lead Sponsor
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
PHASE1/PHASE2Terminated
25 participants
Started: Feb 28, 2014 · Completed: Sep 28, 2020
Locations (1)
Headquarters
Austin, TX, United States
Map
Loading map...